Inspire's Q1 2026 print attributes a combined $120 to $150 million FY26 hit to WISeR plus coding uncertainty, six sell-side analysts cut targets through 7 May, and NeuroPace just received a 43% to 47% Medicare reimbursement increase on the same rule cycle.
Flourish, a New York neuro-AI startup founded in 2024 by Thomas Reardon (Internet Explorer architect at Microsoft in 1994 and CTRL-labs co-founder who sold the company to Meta in 2019 for between $500 million and $1 billion) and former Amazon S-team executive Rob Williams, closed a $500 million round at a $2.5 billion valuation around 4 June 2026. Jeff Bezos contributed close to $100 million after nearly doubling an initial $50 million commitment. Other investors include Lux Capital, GV (Alphabet), and Catalio Capital. The company is building Cortex AI, an architecture-layer system that uses connectomics, the cell-by-cell mapping of biological neural connections, to design AI models that target 20-50 watts of energy draw, roughly the power consumption of a laptop and an order of magnitude lower than a server-grade GPU. Flourish has no product yet.
Neuronoff announced on 5 June 2026 that it has implanted the first patient in a US Department of Defense-funded clinical trial of its Injectrode, a helical platinum-iridium peripheral nerve electrode delivered through a single 18-gauge needle under local anaesthesia, in patients with neurogenic bladder dysfunction following spinal cord injury. The trial (NCT07264868) is being run at UT Health Houston under principal investigator Dr Argyrios Stampas, Professor of Physical Medicine and Rehabilitation at McGovern Medical School. It is a Phase 1/2 randomised controlled study enrolling 21 participants across three arms (unilateral active stimulation, bilateral active stimulation, sham), with primary endpoints at 4 and 8 weeks assessing safety, stimulation accuracy, procedural feasibility, and physician and patient acceptability. This is the first-in-human spinal cord injury trial of the Injectrode.
The Allen Institute announced on 2 June 2026 a $400 million global research initiative called the Brain Health accelerator, targeting neurodegenerative disease at the cell and circuit level. Capital is $200 million from the Allen Institute, $100 million from the Bezos family (whose Bezos Expeditions arm backs Synchron), and $100 million combined from AWS, NIH, and ALS advocacy organisation EverythingALS. The ALS focus is the most direct adjacency to the implantable BCI cohort, which has anchored most of its early commercial work on ALS patients.
Newly filed federal disclosures show that Neuralink has engaged Jeffrey J. Kimbell & Associates and Arnold & Porter Kaye Scholer as its first registered federal lobbyists, with both firms beginning work at the end of April 2026. The scope explicitly names brain-computer interface development and commercialisation plus 'coverage of such devices' as the lobbying focus. The team on the Arnold & Porter side includes former 13-term Wisconsin Democratic Rep. Ron Kind, Senior Counsel at the firm since January 2024 and a former House Ways and Means Committee member overseeing Medicare payment programs. The hire is the first publicly visible step Neuralink has taken toward US Medicare reimbursement positioning for the N1 implant.
France's CEA-Leti announced on 3 June 2026 that it has applied for regulatory authorization to begin BCI4Stroke, a brain-computer interface clinical trial extending the WIMAGINE epidural implant platform into post-stroke rehabilitation. The trial is registered on ClinicalTrials.gov as NCT07477613. WIMAGINE is the same platform that produced the 2019 tetraplegic exoskeleton walking demonstration (Benabid et al., Lancet Neurology) and the 2023 brain-spine interface paralysed-man-walks result with Gert-Jan Oskam (Lorach et al., Nature, the Courtine and Bloch programme). BrainSync is funded under France's €40 million Audace! research programme (France 2030) and the European Innovation Council under Horizon Europe.
Eoin Egan, a 43-year-old Roscommon-born architect and property consultant living in London with motor neurone disease, has gone public as one of seven UK participants in Neuralink's GB-PRIME early feasibility study. Egan received his N1 Implant in December 2025 at UCLH's National Hospital for Neurology and Neurosurgery (Queen Square) in a six-hour robot-performed operation. Four days post-surgery he was driving his wheelchair through a London park with his thoughts alone, using bespoke software built by German assistive technology firm Homebrace that links the BCI cursor to wheelchair steering. He is the third UK GB-PRIME participant to surface publicly, after Paul (October 2025, also MND) and Sebastian Gomez (medical student paralysed in a diving accident).
Sydney and San Francisco-based Omniscient Neurotechnology closed a $27.2 million (AU$41.1 million) Series D funding round on 29 May 2026, co-led by OIF Ventures and the Australian National Reconstruction Fund Corporation. The capital scales the company's FDA-cleared Quicktome connectomics platform for neurosurgical planning, with the company explicitly naming brain-computer interface, stroke, and movement disorders as the next expansion indications. Omniscient is a connectomics company rather than a BCI implant company; the BCI angle is forward-looking adjacency rather than current product.
Rice University and Baylor College of Medicine announced on 28 May 2026 that they have joined the BrainGate research consortium, the multi-institutional clinical brain-computer interface network founded by John Donoghue at Brown University. The Texas team is the sixth in the consortium and the first based outside the eastern and western US clusters. The Rice-Baylor work focuses on decoding cortical neural signals to operate assistive robotic devices that help people with tetraplegia eat and drink independently. The expansion lands the same week Donoghue was named a 2026 Queen Elizabeth Prize for Engineering co-laureate for his BrainGate-anchored work.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.